INTRODUCTION {#s1}
============

Chronic obstructive pulmonary disease (COPD) is the seventh leading cause of death in Taiwan \[[@R1]\]. COPD is increasingly considered a multisystem disease characterized by both pulmonary and systemic inflammation. Comorbidities of COPD generally include diseases involving the pulmonary system (infective exacerbations, pneumonia, influenza, and lung cancer) and cardiovascular system (acute coronary syndrome, endothelial dysfunction, and pulmonary hypertension). COPD is independently associated with increased lung cancer risk, which is probably associated with the inflammation and scarring that occurs during COPD development \[[@R2]--[@R4]\]. Moreover, lung cancer is the leading cause of cancer death in Taiwan \[[@R1]\].

Our previous observational studies have suggested that statin use may reduce the overall risk of cancers and of specific cancers \[[@R5]\], possibly by inhibiting downstream products of the mevalonate pathway \[[@R6]--[@R9]\], triggering tumor-specific apoptosis \[[@R10]\], and inhibiting the proteasome pathway \[[@R11]\]. In theory, statins can reduce COPD-induced inflammation and scarring and further decrease lung cancer risk in patients with COPD. In addition, statins can reduce the risk of esophageal cancer \[[@R12]\], colorectal cancer \[[@R13]\], gastric cancer \[[@R14]\], hepatocellular carcinoma \[[@R15]\], and prostate cancer \[[@R16]\]. However, a meta-analysis indicated that statin use has no effect on lung cancer risk \[[@R17]\]. COPD and lung cancer are associated through several factors in addition to smoking or aeropollutant exposure \[[@R18]--[@R21]\]. Because patients with COPD have a high lung cancer risk, the effect of statins may differ from that observed previously \[[@R17]\].

Statins are the most powerful drugs available for reducing low-density lipoprotein cholesterol (LDL-C) levels; they are the most effective lipid-lowering drugs for improving clinical outcomes when used for the primary and secondary prevention of cardiovascular diseases. Statin selection depends upon several factors, including the degree of hyperlipidemia, pharmacokinetic properties of the drug, drug interactions, presence of renal impairment, and cost. Currently available statins include lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin, and rosuvastatin. These agents are competitive inhibitors of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, which is involved in the rate-limiting step of cholesterol biosynthesis. Statins occupy a portion of the HMG-CoA active site, blocking the binding of the substrate to the enzyme \[[@R22]\]. Most statins reduce LDL-C and triglycerides levels and moderately increase high-density lipoprotein cholesterol (HDL-C) levels; nevertheless, different statins have different efficacies. Whether these differences may be associated with a decrease in lung cancer risk remains unclear.

Thus, considering that systemic inflammation is implicated in lung cancer and that smoking- and obesity-related cancers may remain prevalent in the coming decades, we initiated this study targeting statin-based chemoprevention. Thus far, studies supporting the chemopreventive mechanism of statins against lung cancer in patients with COPD have been scant; in addition, variation in the chemoprevention profiles of individual statins is unclear. This is the first study to establish an association between statin use and the chemoprevention of lung cancer in patients with COPD, and is also the first study to investigate which statins exert the highest chemopreventive effects.

RESULTS {#s2}
=======

Our COPD cohort comprised 43,802 patients, 10,086 (30%) of whom used statins and the remaining 33,716 (70%) of whom did not (Table [1](#T1){ref-type="table"}). The total follow-up duration was 194,933.6 and 80,239.4 person-years for the statin nonusers and users, respectively. Compared with the statin nonusers, the statin users exhibited a higher prevalence of pre-existing medical comorbidities including diabetes, hypertension, and dyslipidemia, along with a higher CCI (all *P* \< 0.001). In addition, significant differences were observed between the two groups in the distributions of age, monthly income, and urbanization level as well as use of nonstatin lipid-lowering drug, aspirin, ACEI, and metformin (Table [1](#T1){ref-type="table"}). A higher proportion of statin nonusers used nonstatin lipid-lowering drugs, metformin, ACEI, and aspirin for \< 28 days; however, most of the statin users used these drugs for \> 365 days. A lower proportion of statin nonusers had a monthly income of NT\$33,301 or more or resided in urban areas. Table [2](#T2){ref-type="table"} shows the lung cancer risk of the statin nonusers and users. After PS adjustment for age, sex, CCI, diabetes, hypertension, dyslipidemia, urbanization level, and monthly income, we analyzed the risk of lung cancer. The adjusted HRs (aHRs) of lung cancer were lower in the statin users than in the statin nonusers (aHR = 0.37, 95% confidence interval \[CI\]: 0.31 to 0.44). The stratified analysis showed that the aHRs were significantly lower in the statin users, particularly those aged 65--74 years, regardless of sex. Specifically, the aHRs of lung cancer were lower in the statin users than in the statin nonusers for every age group (40--64, 65--74, and ≥ 75 years; aHRs = 0.37, 0.31, and 0.43, respectively). The statin users also exhibited lower lung cancer aHRs than did the statin nonusers after sex stratification (women: aHR = 0.34, 95% CI: 0.25 to 0.45; men: aHR = 0.39, 95% CI: 0.32 to 0.48).

###### Characteristics of the sample population

                                                Entire cohort (*n* = 43,802)   Patients using statins (≥ 28 cDDDs; *n* = 10,086)   Patients not using statins (\< 28 cDDDs; *n* = 33,716)   *P*[^a^](#tfn_001){ref-type="table-fn"}                   
  --------------------------------------------- ------------------------------ --------------------------------------------------- -------------------------------------------------------- ----------------------------------------- ------- ------- ----------
  **Age, years (mean ± SD)**                    62.92 (13.18)                  61.55 (10.97)                                       63.33 (13.74)                                            \< 0.001                                                  
   40--54                                       14458                          33.01                                               3180                                                     31.53                                     11278   33.45   \< 0.001
   55--64                                       9644                           22.02                                               2899                                                     28.74                                     6745    20.01   
   65--74                                       10455                          23.87                                               2777                                                     27.53                                     7678    22.77   
   ≥ 75                                         9245                           21.11                                               1230                                                     12.20                                     8015    23.77   
  **Sex**                                                                                                                                                                                                                                             
   Female                                       19715                          45.01                                               5150                                                     51.06                                     14565   43.20   \< 0.001
   Male                                         24087                          54.99                                               4936                                                     48.94                                     19151   56.80   
  **CCI[^+^](#tfn_002){ref-type="table-fn"}**                                                                                                                                                                                                         
   0                                            11279                          25.75                                               2586                                                     25.64                                     8693    25.78   \< 0.001
   1                                            12597                          28.76                                               3014                                                     29.88                                     9583    28.42   
   2                                            9075                           20.72                                               2195                                                     21.76                                     6880    20.41   
   ≥ 3                                          10851                          24.77                                               2291                                                     22.71                                     8560    25.39   
  **Diabetes**                                                                                                                                                                                                                                        
   No                                           33491                          76.46                                               6819                                                     67.61                                     26672   79.11   \< 0.001
   Yes                                          10311                          23.54                                               3267                                                     32.39                                     7044    20.89   
  **Hypertension**                                                                                                                                                                                                                                    
   No                                           22067                          50.38                                               4158                                                     41.23                                     17909   53.12   \< 0.001
   Yes                                          21735                          49.62                                               5928                                                     58.77                                     15807   46.88   
  **Dyslipidemia**                                                                                                                                                                                                                                    
   No                                           31731                          72.44                                               5785                                                     57.36                                     25946   76.95   \< 0.001
   Yes                                          12071                          27.56                                               4301                                                     42.64                                     7770    23.05   
  **Nonstatin lipid-lowering drugs**                                                                                                                                                                                                                  
   \< 28 days                                   39267                          89.65                                               7212                                                     71.51                                     32055   95.07   \< 0.001
   28--365 days                                 3186                           7.27                                                1923                                                     19.07                                     1263    3.75    
   \> 365 days                                  1349                           3.08                                                951                                                      9.43                                      398     1.18    
  **Metformin**                                                                                                                                                                                                                                       
   \< 28 days                                   35961                          82.10                                               6286                                                     62.32                                     29675   88.01   \< 0.001
   28--365 days                                 2684                           6.13                                                964                                                      9.56                                      1720    5.10    
   \> 365 days                                  5157                           11.77                                               2836                                                     28.12                                     2321    6.88    
  **ACEI**                                                                                                                                                                                                                                            
   \< 28 days                                   23928                          54.63                                               3066                                                     30.40                                     20862   61.88   \< 0.001
   28--365 days                                 7925                           18.09                                               1928                                                     19.12                                     5997    17.79   
   \> 365 days                                  11949                          27.28                                               5092                                                     50.49                                     6857    20.34   
  **Aspirin**                                                                                                                                                                                                                                         
   \< 28 days                                   28319                          64.65                                               4161                                                     41.26                                     24158   71.65   \< 0.001
   28--365 days                                 7385                           16.86                                               2296                                                     22.76                                     5089    15.09   
   \> 365 days                                  8098                           18.49                                               3629                                                     35.98                                     4469    13.25   
  **Urbanization level**                                                                                                                                                                                                                              
   Urban                                        30539                          69.72                                               7208                                                     71.47                                     23331   69.20   \< 0.001
   Suburban                                     8914                           20.35                                               1920                                                     19.04                                     6994    20.74   
   Rural                                        4349                           9.93                                                958                                                      9.50                                      3391    10.06   
  **Monthly income (NT\$)**                                                                                                                                                                                                                           
   0                                            3464                           7.91                                                795                                                      7.88                                      2669    7.92    \< 0.001
   1--21,000                                    15001                          34.25                                               3067                                                     30.41                                     11934   35.40   
   21,000--33,300                               12904                          29.46                                               3165                                                     31.38                                     9739    28.89   
   ≥ 33,301                                     12433                          28.38                                               3059                                                     30.33                                     9374    27.80   

Comparison between statin use and no statin use.

CCI: Charlson comorbidity index.

###### Risk of lung cancer in statin users and nonusers in the study cohort

  Entire cohort (*n* = 43,802)                                Patients not using statins (Total follow-up: 194,933.6 person-years)   Patients using statins (Total follow-up: 80,239.4 person-years)   aHR[†](#tfn_008){ref-type="table-fn"} (95% CI)                          
  ----------------------------------------------------------- ---------------------------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------------ ---------------------- -------------------------
  **Entire cohort**                                           1225                                                                   628.4 (593.2, 663.6)                                              159                                              198.2 (167.4, 229.0)   0.37 (0.31, 0.44)\*\*\*
  **Age, 40--64 years[^a^](#tfn_003){ref-type="table-fn"}**   419                                                                    360.5 (326.0, 395.0)                                              66                                               130.8 (99.2, 162.3)    0.37 (0.29, 0.49)\*\*\*
  **Age, 65--74 years[^b^](#tfn_004){ref-type="table-fn"}**   415                                                                    930.2 (840.7, 1019.7)                                             56                                               257.1 (189.8, 324.5)   0.31 (0.23, 0.41)\*\*\*
  **Age, ≥ 75 years[^c^](#tfn_005){ref-type="table-fn"}**     391                                                                    1146.9 (1033.2, 1260.6)                                           37                                               463.4 (314.1, 612.7)   0.43 (0.31, 0.61)\*\*\*
  **Female[d](#tfn_006){ref-type="table-fn"}**                361                                                                    413.1 (370.5, 455.7)                                              57                                               136.3 (100.9, 171.6)   0.34 (0.25, 0.45)\*\*\*
  **Male[e](#tfn_007){ref-type="table-fn"}**                  864                                                                    803.4 (749.8, 857.0)                                              102                                              265.6 (214.0, 317.1)   0.39 (0.32, 0.48)\*\*\*

Total follow-up 116,228.5 person-year for patients not using statins and 50,476.0 for patients using statins.

Total follow-up 44,612.9 person-year for patients not using statins and 21,778.3 for patients using statins.

Total follow-up 34,092.2 person-year for patients not using statins and 7,985.1 for patients using statins.

Total follow-up 87,389.9 person-year for patients not using statins and 41,828.7 for patients using statins.

Total follow-up 107,543.7 person-year for patients not using statins and 38,410.7 for patients using statins.

CI: confidence interval.

aHR: adjusted hazard ratio.

Main model was adjusted using propensity scores for age, sex, Charlson comorbidity index, diabetes, hypertension, dyslipidemia, urbanization level, and monthly income.

Statins dose-dependently reduced the risk of lung cancer in different cDDD subgroups; the main model was PS adjusted for age, sex, CCI, diabetes, hypertension, dyslipidemia, urbanization level, and monthly income (Table [3](#T3){ref-type="table"}). Lipophilia statins comprised simvastatin, lovastatin, atorvastatin, and fluvastatin, whereas hydrophilia statins comprised pravastatin and rosuvastatin. Table [3](#T3){ref-type="table"} presents the lung cancer risk reduction demonstrated by lipophilia and hydrophilia statins in patients with COPD along with the doses and responses (*P* for trend \< 0.001). Among individual statins, lovastatin and fluvastatin did not reduce the risk of lung cancer in patients with COPD significantly. The aHRs of lung cancer for patients using rosuvastatin, simvastatin, atorvastatin, and pravastatin were lower compared with that of statin nonusers (aHRs = 0.41, 0.44, 0.52 and 0.58, respectively). Our results revealed that individual statins reduced lung cancer risk at varying efficacies among COPD patients.

###### Incidence rate and adjusted hrs of lung cancer associated with statin use during the follow-up period in COPD patients

  Variable                                                               No. of Patients   No. of Person-Years   No. of Patients With Lung cancer   Incidence Rate (per 105 person-years) (95% C.I.)   Adjusted HR (95% C.I.)    *P* for Trend
  ---------------------------------------------------------------------- ----------------- --------------------- ---------------------------------- -------------------------------------------------- ------------------------- ---------------
  Total statin use                                                                                                                                                                                                               
   Nonuser (\< 28 cDDDs)                                                 33716             194933.6              1225                               628.4 (593.2, 663.6)                               1.00                      \< 0.001
   User (≥ 28 cDDDs)                                                     10086             80239.4               159                                198.2 (167.4, 229.0)                               0.37 (0.31, 0.44)\*\*\*   
   28--90 cDDDs                                                          2346              17095.6               49                                 286.6 (206.4, 366.9)                               0.50 (0.38, 0.67)\*\*\*   
   91.365 cDDDs                                                          3215              24193.1               57                                 235.6 (174.4, 296.8)                               0.43 (0.33, 0.56)\*\*\*   
   \> 365 cDDDs                                                          4525              38950.7               53                                 136.1 (99.4, 172.7)                                0.27 (0.20, 0.35)\*\*\*   
  Lipophilia statin use[†](#tfn_009){ref-type="table-fn"}                                                                                                                                                                        
   Nonuser (\< 28 cDDDs)                                                 35008             204288.0              1248                               610.9 (577.0, 644.8)                               1.00                      \< 0.001
   User (≤ 28 cDDDs)                                                     8794              70885.0               136                                191.9 (159.6, 224.1)                               0.44 (0.37, 0.53)\*\*\*   
   28--90 cDDDs                                                          2296              17069.8               46                                 269.5 (191.6, 347.4)                               0.53 (0.40, 0.71)\*\*\*   
   91--365 cDDDs                                                         3012              23258.7               47                                 202.1 (144.3, 259.8)                               0.45 (0.34, 0.61)\*\*\*   
   \> 365 cDDDs                                                          3486              30556.4               43                                 140.7 (98.7, 182.8)                                0.36 (0.26, 0.49)\*\*\*   
  Hydrophilia statin use[‡](#tfn_010){ref-type="table-fn"}                                                                                                                                                                       
   Nonuser (\< 28 cDDDs)                                                 39878             242812.7              1339                               551.5 (521.9, 581.0)                               1.00                      \< 0.001
   User (≤ 28 cDDDs)                                                     3924              32360.4               45                                 139.1 (98.4, 179.7)                                0.45 (0.33, 0.62)\*\*\*   
   28--90 cDDDs                                                          1122              8876.1                18                                 202.8 (109.1, 296.5)                               0.59 (0.37, 0.95)\*       
   91--365 cDDDs                                                         1531              12432.2               13                                 104.6 (47.7, 161.4)                                0.35 (0.20, 0.61)\*\*\*   
   \> 365 cDDDs                                                          1271              11052.0               14                                 126.7 (60.3, 193.0)                                0.44 (0.26, 0.75)\*\*     
  Individual statin use (≤ 28 cDDDs)[‡](#tfn_010){ref-type="table-fn"}                                                                                                                                                           
   Simvastatin                                                           3418              28625.0               37                                 129.3 (87.6, 170.9)                                0.44 (0.31, 0.62)\*\*\*   
   Lovastatin                                                            2109              18281.5               40                                 218.8 (151.0, 286.6)                               0.74 (0.54, 1.03)         
   Atorvastatin                                                          5484              44678.1               81                                 181.3 (141.8, 220.8)                               0.52 (0.41, 0.66)\*\*\*   
   Fluvastatin                                                           1510              12855.7               27                                 210.0 (130.8, 289.2)                               0.75 (0.51, 1.11)         
   Pravastatin                                                           1501              12654.5               19                                 150.1 (82.6, 217.7)                                0.58 (0.36, 0.91)\*       
   Rosuvastatin                                                          2741              22641.7               28                                 123.7 (77.9, 169.5)                                0.41 (0.28, 0.59)\*\*\*   

Main model is adjusted for age, sex, Charlson comorbidity index, diabetes, hypertension, dyslipidemia, level of urbanization, Monthly income in propensity score.

Lipophilia statins include simvastatin, lovastatin, atorvastatin, and fluvastatin. Hydrophilia statins include pravastatin and rosuvastatin.

The HRs of individual statin users (. 28 cDDDs) were compared with nonusers (\< 28 cDDDs).

In the sensitivity analysis, PS adjustments were made to estimate the associations of age, sex, CCI, diabetes, hypertension, dyslipidemia, urbanization level, monthly income, and nonstatin lipid-lowering drugs, metformin, ACEI, and aspirin use with the incidence of lung cancer in different models. Table [4](#T4){ref-type="table"} shows that the effects of statins remained significant in the subgroups of various covariates when the main model was adjusted for PSs. Statins dose-dependently reduced the risk of lung cancer in all subgroups and the main model with additional covariates (nonstatin lipid-lowering drugs, metformin, ACEI, or aspirin use). All aHRs indicated that statins dose-dependently induced significant reductions in lung cancer risk in all subgroups, regardless of comorbidities or drug use (*P* \< 0.001). Thus, our data revealed that statins show a dose-dependent chemopreventive effect against lung cancer.

###### Sensitivity analysis of ahrs of statin use for reduction of lung cancer risk

                                                                Statin use [a](#tfn_014){ref-type="table-fn"}HR (95% CI)   *P* for trend                                                                                                                                                                    
  ------------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ----------
  **Main model[†](#tfn_016){ref-type="table-fn"}**              1.00                                                       0.50 (0.38, 0.67)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.43 (0.33, 0.56)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.27 (0.20, 0.35)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
  **Additional covariates[‡](#tfn_017){ref-type="table-fn"}**                                                                                                                                                                                                                                               
   Main model + Nonstatin lipid-lowering drugs                  1.00                                                       0.52 (0.39, 0.69)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.46 (0.35, 0.60)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.29 (0.22, 0.38)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
   Main model + Metformin                                       1.00                                                       0.51 (0.38, 0.67)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.45 (0.34, 0.58)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.28 (0.21, 0.38)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
   Main model + ACEI                                            1.00                                                       0.52 (0.39, 0.69)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.48 (0.37, 0.63)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.33 (0.25, 0.43)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
   Main model + Aspirin                                         1.00                                                       0.52 (0.39, 0.69)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.46 (0.35, 0.61)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.30 (0.23, 0.40)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
  **Subgroup effects**                                                                                                                                                                                                                                                                                      
   Age, years 40--64                                            1.00                                                       0.62 (0.41, 0.94)[\*](#tfn_011){ref-type="table-fn"}       0.41 (0.27, 0.64)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.23 (0.14, 0.36)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
   65--74                                                       1.00                                                       0.33 (0.18, 0.58)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.45 (0.30, 0.67)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.22 (0.14, 0.35)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
   ≥ 75                                                         1.00                                                       0.59 (0.34, 1.03)                                          0.35 (0.19, 0.66)[\*\*](#tfn_012){ref-type="table-fn"}     0.39 (0.23, 0.67)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
  Sex                                                                                                                                                                                                                                                                                                       
   Female                                                       1.00                                                       0.28 (0.15, 0.53)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.44 (0.29, 0.68)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.30 (0.20, 0.45)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
   Male                                                         1.00                                                       0.64 (0.46, 0.88)[\*\*](#tfn_012){ref-type="table-fn"}     0.43 (0.30, 0.60)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.24 (0.16, 0.35)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
  CCI[^+^](#tfn_014){ref-type="table-fn"}                                                                                                                                                                                                                                                                   
   0                                                            1.00                                                       0.47 (0.27, 0.84)[\*](#tfn_011){ref-type="table-fn"}       0.32 (0.17, 0.58)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.29 (0.18, 0.49)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
   1                                                            1.00                                                       0.52 (0.32, 0.87)[\*](#tfn_011){ref-type="table-fn"}       0.53 (0.35, 0.82)[\*\*](#tfn_012){ref-type="table-fn"}     0.21 (0.12, 0.37)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
   2                                                            1.00                                                       0.44 (0.23, 0.83)[\*](#tfn_011){ref-type="table-fn"}       0.59 (0.36, 0.97)[\*](#tfn_011){ref-type="table-fn"}       0.28 (0.15, 0.50)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
   ≥ 3                                                          1.00                                                       0.53 (0.29, 0.98)[\*](#tfn_011){ref-type="table-fn"}       0.23 (0.11, 0.48)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.25 (0.13, 0.46)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
  Diabetes                                                                                                                                                                                                                                                                                                  
   No                                                           1.00                                                       0.51 (0.37, 0.71)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.46 (0.34, 0.63)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.22 (0.16, 0.33)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
   Yes                                                          1.00                                                       0.46 (0.25, 0.83)[\*](#tfn_011){ref-type="table-fn"}       0.33 (0.20, 0.56)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.30 (0.20, 0.47)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
  Dyslipidemia                                                                                                                                                                                                                                                                                              
   No                                                           1.00                                                       0.47 (0.33, 0.67)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.44 (0.32, 0.62)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.24 (0.16, 0.35)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
   Yes                                                          1.00                                                       0.53 (0.33, 0.86)[\*](#tfn_011){ref-type="table-fn"}       0.39 (0.25, 0.60)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.28 (0.19, 0.42)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
  Hypertension                                                                                                                                                                                                                                                                                              
   No                                                           1.00                                                       0.50 (0.33, 0.75)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.50 (0.34, 0.73)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.22 (0.13, 0.36)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
   Yes                                                          1.00                                                       0.50 (0.33, 0.74)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.37 (0.25, 0.53)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.27 (0.19, 0.38)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
  Nonstatin lipid-lowering drugs                                                                                                                                                                                                                                                                            
   \< 28 days                                                   1.00                                                       0.53 (0.39, 0.73)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.42 (0.31, 0.58)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.25 (0.18, 0.35)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
   28--365 days                                                 1.00                                                       0.49 (0.19, 1.26)                                          0.46 (0.22, 0.96)[\*](#tfn_011){ref-type="table-fn"}       0.32 (0.16, 0.63)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
   \> 365 days                                                  1.00                                                       0.50 (0.06, 4.18)                                          1.47 (0.49, 4.38)                                          0.70 (0.24, 2.02)                                          0.644
  Metformin                                                                                                                                                                                                                                                                                                 
   \< 28 days                                                   1.00                                                       0.53 (0.38, 0.72)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.42 (0.30, 0.58)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.27 (0.19, 0.38)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
   28--365 days                                                 1.00                                                       0.29 (0.09, 0.93)[\*](#tfn_011){ref-type="table-fn"}       0.28 (0.10, 0.78)[\*](#tfn_011){ref-type="table-fn"}       0.25 (0.09, 0.69)[\*\*](#tfn_012){ref-type="table-fn"}     \< 0.001
   \> 365 days                                                  1.00                                                       0.74 (0.32, 1.71)                                          0.78 (0.44, 1.38)                                          0.38 (0.23, 0.65)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.001
  ACEI                                                                                                                                                                                                                                                                                                      
   \< 28 days                                                   1.00                                                       0.56 (0.38, 0.84)[\*\*](#tfn_012){ref-type="table-fn"}     0.44 (0.29, 0.68)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.21 (0.11, 0.41)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
   28--365 days                                                 1.00                                                       0.53 (0.30, 0.93)[\*](#tfn_011){ref-type="table-fn"}       0.68 (0.42, 1.10)                                          0.32 (0.16, 0.63)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
   \> 365 days                                                  1.00                                                       0.64 (0.35, 1.18)                                          0.56 (0.34, 0.91)[\*](#tfn_011){ref-type="table-fn"}       0.51 (0.35, 0.74)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
  Aspirin                                                                                                                                                                                                                                                                                                   
   \< 28 days                                                   1.00                                                       0.44 (0.29, 0.67)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.39 (0.26, 0.60)[\*\*\*](#tfn_013){ref-type="table-fn"}   0.30 (0.19, 0.47)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
   28--365 days                                                 1.00                                                       0.51 (0.29, 0.89)[\*](#tfn_011){ref-type="table-fn"}       0.74 (0.47, 1.17)                                          0.19 (0.09, 0.44)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001
   \> 365 days                                                  1.00                                                       1.13 (0.65, 1.97)                                          0.52 (0.30, 0.92)[\*](#tfn_011){ref-type="table-fn"}       0.46 (0.30, 0.71)[\*\*\*](#tfn_013){ref-type="table-fn"}   \< 0.001

*p* \< 0.05

*p* \< 0.01

*p* \< 0.001.

HR: adjusted hazard ratio.

CCI: Charlson comorbidity index.

Main model was adjusted using propensity scores for age, sex, Charlson comorbidity index, diabetes, hypertension, dyslipidemia, urbanization level, and monthly income.

Models were adjusted for covariates in the main model as well as each additional listed covariate.

DISCUSSION {#s3}
==========

Recently, interest in the function of systemic inflammation in COPD has been increasing \[[@R23]--[@R27]\]. Epidemiological studies have shown that elevated levels of systemic inflammatory markers, particularly C-reactive protein (CRP), interleukin 6 (IL-6), and fibrinogen, predict poor outcomes in COPD, including accelerated loss of lung function, greater propensity for infective exacerbations, and greater mortality \[[@R28]--[@R30]\]. This systemic inflammation has three likely mechanisms. The first is a "spillover" effect from inflammation (driven primarily in the lungs in response to aeropollutants, mainly cigarette smoke) to neutrophilic inflammation and finally to recurrent infection \[[@R31], [@R32]\]. The second is the existence of an inherent systemic-based proinflammatory state conferred by a genetic disposition \[[@R23], [@R33], [@R34]\]. Smoking, as a recurring proinflammatory stimulus to the pulmonary and immune systems, considerably enhances this inflammatory disposition. The final possible mechanism is elevated systemic inflammation, which has been linked to progressive loss of lung function \[[@R24]--[@R27], [@R35]--[@R37]\] and to many types of cancer \[[@R37]--[@R39]\].

CRP is mainly a marker of inflammation. When some organs are chronically inflamed, they are at greater cancer risk \[[@R40], [@R41]\]. Increased CRP levels are associated with increased cancer risk \[[@R42]\]. A large-scale prospective study reported the effects of statins on mortality in patients with COPD by using the Rotterdam study data; stratification by high-sensitivity CRP revealed that all-cause mortality was 78% lower among patients with CRP ≥ 3 mg/L, whereas it was only by 21% lower among those with CRP \< 3 mg/L \[[@R43]\]. The authors concluded that statins therapy primarily benefited the all-cause mortality of patients whose CRP levels indicated underlying systemic inflammation \[[@R43]\].

Statins attenuate both pulmonary and systemic inflammation through their effects on the NF-κB/STAT3 proinflammatory pathways \[[@R23]\]. Statins are considered effective anti-inflammatory agents that reduce the levels of systemic markers (IL-6 and CRP) by more than 50% in a few days \[[@R44]\]. Statins exhibit immune-modulating (i.e., anti-inflammatory) effects that may be particularly crucial in COPD, in which both pulmonary and systemic inflammation are believed to be central causes of symptoms (exertional breathlessness, cough, and fatigue), hospitalization, and premature death (from pulmonary infection or exacerbation, lung cancer, and cardiac disease). Therefore, a great need exists for novel COPD treatments that minimize neutrophil-driven pulmonary and systemic inflammation that alters the natural history of the disease by slowing lung function decline, minimizing cardiovascular and respiratory infection-related morbidities, and reducing cancer risk \[[@R23]\]. A meta-analysis showed no effect statin use on the risk of lung cancer \[[@R17]\]; nevertheless, in the present study, COPD patients with a high risk of lung cancer who used statins exhibited a 63% reduced lung cancer risk (Table [2](#T2){ref-type="table"}). This is the first study to report that statin-based agents could be of chemopreventive value against lung cancer, specifically for patients with COPD.

Rosuvastatin, atorvastatin, and simvastatin cause the greatest percentage change in LDL-C; thus, they are preferred for use in patients who require a potent statin because of high cardiovascular risk or who require a \> 35% reduction in LDL-C level. Rosuvastatin is relatively more potent than atorvastatin \[[@R45], [@R46]\] and both are significantly more potent than simvastatin, lovastatin, pravastatin, or fluvastatin \[[@R46], [@R47]\]. At their maximal prescribed doses, rosuvastatin and atorvastatin cause LDL-C level reductions greater than those caused by other available statins. Statin therapy typically increases HDL-C levels; however, these effects vary depending on the statin type and are not correlated with the effects on LDL-C levels. For example, simvastatin and rosuvastatin increase HDL-C levels as their doses are increased, whereas at higher doses, atorvastatin attenuates increases in HDL-C levels \[[@R48]\]. Atorvastatin and rosuvastatin are more effective for reducing triglyceride levels in patients with hypercholesterolemia than other statins are \[[@R46], [@R49]--[@R51]\]. Our results revealed that different statins were associated with varying reductions in lung cancer risk among the COPD patients (Table [3](#T3){ref-type="table"}). Notably, the stronger efficacies of rosuvastatin, atorvastatin, and simvastatin in reducing LDL-C and triglyceride levels and increasing high HDL-C levels were proportional to the decreased aHRs of lung cancer risk (Table [3](#T3){ref-type="table"}). No clear data regarding the use of different individual statins has been previously reported \[[@R17]\]. In our study, lovastatin and fluvastatin exhibited no significant reduction in lung cancer risk in patients with COPD. We are the first to report that rosuvastatin, atorvastatin, and simvastatin show stronger chemopreventive effect against lung cancer risk in patients with COPD. Of these, rosuvastatin exhibited the highest chemopreventive potential, followed by simvastatin and atorvastatin.

Statin use dose-dependently reduced lung cancer risk in the COPD patients and in the main model with additional covariates (Table [4](#T4){ref-type="table"}). The use of aspirin, nonstatins lipid-lowering drugs, metformin, and ACEI also has an anticancer effect \[[@R5]\]. When the cDDDs of aspirin, metformin, and ACEI were \> 365, the chemopreventive effect of statins against lung cancer was masked (Table [4](#T4){ref-type="table"}). However, our sensitivity analysis indicated that when the cDDDs of statins increased to \> 365, the aHRs of lung cancer risk in the COPD patients decreased significantly. However, the aHRs of lung cancer risk were nonsignificant when the cDDDs of nonstatin lipid-lowering drugs were \> 365 (Table [4](#T4){ref-type="table"}). These outcomes might explain the independent chemopreventive effects of aspirin, metformin, ACEI, and statins. However, unknown associations between nonstatin lipid-lowering drugs and statins were observed in the reduction of lung cancer risk in the COPD patients. This study is also the first report that statins exert dose--response and chemopreventive effects against lung cancer in patients with COPD.

However, this study has potential limitations. The biases of additional risk factors associated with COPD and lung cancer, including indoor and outdoor air pollution, domestic use of biomass fuels, occupational exposure to dust and fumes, and smoking could not be eliminated \[[@R52], [@R53]\]. A future large-scale randomized trial with a suitable regimen in well-selected patients must compare standard approaches to obtain this crucial information. However, methodological issues may obscure the precise relationship between these factors and lung cancer risk. According to one theory, higher urbanization levels and income are associated with lower lung cancer risk. In our study, we used PSs to match age, sex, CCI, diabetes, hypertension, dyslipidemia, urbanization level, and monthly income. Urbanization level and monthly income are nonvalidated alternatives to lifestyle factors and environmental levels. To obtain more appropriate information, a large-scale randomized trial should apply a suitable regimen to appropriately selected patients for comparing standard approaches. Moreover, in this study, the diagnoses of lung cancer and all other comorbidities were completely dependent on ICD codes. However, the NHI Administration randomly reviews medical records and interviews patients to validate diagnoses. Hospitals with outlier diagnoses and practices may be audited and penalized heavily if malpractice or discrepancies are discovered. Another limitation is that information regarding several unmeasured confounders, including body mass index, smoking, alcohol intake, and use of other over-the-counter drugs (some of which are associated with lung cancer), is unavailable in the NHIRD. However, considering the magnitude and significance of the observed effects, it is unlikely that these limitations compromised the results. Finally, this was not a prospective randomized blinded study; hence, a cause--effect relationship could not be established. The findings of this study suggest that statins dose-dependently exert a significant chemopreventive effect against lung cancer in COPD patients. Additional randomized studies are required to verify these findings.

MATERIALS AND METHODS {#s4}
=====================

The National Health Insurance (NHI) program, which was established in 1995, currently provides comprehensive health insurance coverage to 98% of the more than 23 million people in Taiwan. In this study, we used data from the National Health Insurance Research Database (NHIRD). No statistically significant differences were observed in age, sex, or health care costs between the NHIRD sample group and all NHI enrollees. Data that could be used to identify patients or care providers, including medical institutions and physicians, are encrypted before being sent to the National Health Research Institutes for construction of the NHIRD. The Institutes further encrypts the data before being releasing the database to researchers. Theoretically, the NHIRD data alone is insufficient to identify any individual. All researchers using the NHIRD and its data subsets must sign a written agreement declaring that they have no intention of attempting to obtain information that could potentially violate the privacy of patients or care providers \[[@R5]\].

Our study cohort comprised all patients diagnosed with COPD (according to International Classification of Diseases, Ninth Revision, Clinical Modification \[ICD-9-CM\] codes) at health care facilities in Taiwan (*n* = 116,017) between January 1, 2001 and December 31, 2012. We excluded patients without a subsequent outpatient visit, emergency department visit, or inpatient hospitalization for COPD within 12 months of the first presentation (*n* = 48,212); these patients were considered to not have COPD (Figure [1](#F1){ref-type="fig"}). We also excluded 15,436 patients who were younger than 40 years old (*n* = 52,369) and had any inpatient or outpatient diagnosis related to cancer before the enrollment date (*n* = 5,353) or had any statin prescribed within 6 months before the index date (*n* = 3,214).

![Patient selection flowchart](oncotarget-07-59618-g001){#F1}

Our final study cohort contained 43,802 patients diagnosed with COPD in Taiwan over the 11-year period, 10,086 of whom used statins and 33,716 of whom did not. Each patient was followed to assess lung cancer risk or protective factors. In addition, we considered the demographic characteristics of age and sex; comorbidities of diabetes, hypertension, dyslipidemia, and Charlson comorbidity index (CCI); urbanization level; monthly income; and use of nonstatin lipid-lowering drugs, metformin, aspirin, and angiotensin-converting enzyme inhibitor (ACEI). The index date of statin use was the date of COPD confirmation. Because we aimed to evaluate the preventive effects of statin use in COPD patients who have a high lung cancer risk, the primary endpoint was lung cancer risk and the secondary endpoints were different benefits if different doses or types of statins used. The defined daily dose (DDD)---recommended by the World Health Organization---is a measure of the prescribed drug amount. DDD is the assumed average maintenance dose per day of a drug consumed for its main indication in adults.^12^ To examine the dose--response relationship, we categorized statin use into four groups in each cohort (\< 28, 28--90, 91--365, and \> 365 cumulative DDDs \[cDDDs\]) because the duration of the refill card was 3 months. Patients receiving \< 28 cDDDs were defined as nonstatin users (Tables [2](#T2){ref-type="table"}--[4](#T4){ref-type="table"}) \[[@R54]\]. Furthermore, to examine the preventive effect of different types of statins, we categorized statin use into different individual statin use groups in each cohort (Table [3](#T3){ref-type="table"}).

Propensity scores (PSs) were derived using a logistic regression model to estimate the effect of statins by accounting for the covariates predicting receiving the intervention (statins). This method is commonly used in observational studies to reduce selection bias \[[@R55]\]. The covariates in the main model were PS adjusted for age, sex, CCI, diabetes, hypertension, dyslipidemia, urbanization level, and monthly income in New Taiwan dollars (NT\$0, NT\$1--21,000, NT\$21,000--33,300; and ≥ NT\$33,301) (Table [2](#T2){ref-type="table"}). The endpoint for both statin users and nonusers was the diagnosis of lung cancer (ICD-9-CM 162) with a subsequent outpatient visit, emergency department visit, or inpatient hospitalization for lung cancer within 12 months of diagnosis; the nonusers were used as the reference arm. The cumulative incidence of lung cancer in the two groups was estimated using the Kaplan--Meier method.

A time-dependent Cox proportional hazard model was used to calculate the hazard ratios (HRs) of lung cancer in the statin users and nonusers. The HRs were adjusted for age, sex, CCI, diabetes, hypertension, dyslipidemia, urbanization level, and monthly income in the multivariate analysis. A stratified analysis was conducted to evaluate the effect of statin use on age and sex (Table [2](#T2){ref-type="table"}). All analyses were conducted using SAS software (Version 9.3; SAS, Cary, NC, USA); two-tailed *P* \< 0.05 was considered significant. In sensitivity analyses, external adjustments are used to improve the understanding of the effects of drugs and other covariates in epidemiological database studies \[[@R56]\]. Hence, in our sensitivity analyses, data were adjusted in different models to estimate the association of lung cancer incidence with age, sex, diabetes, dyslipidemia, hypertension, CCI, anxiety disorder, and the use of nonstatin lipid-lowering drugs, metformin, aspirin, and ACEI. The drug use-stratified models were adjusted for covariates in the main model and for each additional covariate (Table [4](#T4){ref-type="table"}).

CONCLUSIONS {#s5}
===========

Statins dose-dependently exert a significant chemopreventive effect against lung cancer in COPD patients. Rosuvastatin shows the highest chemopreventive potential, followed by simvastatin and atorvastatin.
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